Aducanumab dosage and usage

Aducanumab (Aducanumab) should be administered according to your physician's prescription and guidance, as this is a conditionally approved drug and its use requires careful monitoring and supervision by a medical professional. The following are general dosage guidelines, but be sure to follow your doctor's specific recommendations:

1. Dosage: Aducanumab is usually given as an intravenous injection once a month. The dose per injection is 10mg/ml. Initial treatment usually starts with a low dose and then gradually increases the dose to reduce potential side effects. The doctor will determine dosage adjustments based on the patient's specific situation and needs.

2. Treatment plan: Treatment with aducanumab usually includes initial treatment and maintenance treatment. The goal of initial treatment is to gradually increase the dose to ensure that the patient tolerates the drug and reduces side effects. The patient then enters the maintenance treatment phase, where he continues to receive higher doses of medication to maintain efficacy.

3. Management and Monitoring: The use of aducanumab needs to be under the supervision of a physician, who will closely monitor the patient's condition and response. During treatment, patients will need regular medical evaluations, including cognitive function tests and neuroimaging, to assess the drug's impact on the disease.

4. Injection process: Injection of aducanumab needs to be performed by professional medical personnel, usually in a medical institution or clinic. Patients need to go to a medical facility regularly to receive injections, and each injection takes a while to complete.

5. Duration of treatment: Treatment with aducanumab is usually long-term because Alzheimer's disease is a progressive disease and the goal of treatment is to slow the progression of the disease. The duration of treatment will be determined based on the patient's condition and response.

6. Follow medical advice: Patients must strictly follow the doctor's recommendations and prescriptions and may not change the dosage or treatment plan on their own. If patients have any concerns, side effects or discomfort, they should report to their doctor promptly.

It is important to emphasize that the use of aducanumab is complex and its therapeutic efficacy is still being studied and evaluated. Therefore, patients should actively cooperate with the medical team, closely follow the doctor's recommendations, and participate in clinical monitoring to ensure the best treatment results. Medication dosage and usage will change based on scientific research and developments in medical practice, so patients should always consult their doctor for the latest information.

xa0